Quentin Mark Anstee
783 works · 72,286 citations · h-index 115
Top works
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
- Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research
- TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
- From NASH to HCC: current concepts and future challenges
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study